Riyadh Pharma Medical & Cosmetic Products Co Ltd's strategic aim is to strengthen its position within consumer health. The company is expected to continue forging partnerships with key international players through licensing agreements. These agreements are expected to be in line with consumer expectations in terms of the range of generic products and branded products it offers. Its low-price positioning is set to remain a major asset in its attempts to target middle-income and low-income...
Euromonitor International Local Company Profiles are a concise set of briefings detailing the strategic direction taken by a company. Discover key contact details, the company background and their competitive positioning through this collection of snapshot company profiles.
Product coverage: Allergy Care, Herbal/Traditional Products, OTC, Paediatric Consumer Health, Sports Nutrition, Vitamins and Dietary Supplements, Weight Management.
Data coverage: market sizes (historic and forecasts), company shares, brand shares and distribution data.
Why buy this report?
* Get a detailed picture of the Consumer Health market;
* Pinpoint growth sectors and identify factors driving change;
* Understand the competitive environment, the market’s major players and leading brands;
* Use five-year forecasts to assess how the market is predicted to develop.
RIYADH PHARMA MEDICAL & COSMETIC PRODUCTS CO LTD IN CONSUMER HEALTH (SAUDI ARABIA)
LIST OF CONTENTS AND TABLES
Summary 1 Riyadh Pharma Medical & Cosmetic Products Co Ltd: Key Facts
Summary 2 Riyadh Pharma Medical & Cosmetic Products Co Ltd: Operational Indicators
Summary 3 Riyadh Pharma Medical & Cosmetic Products Co Ltd: Competitive Position 2015
Saudi Arabia Infrastructure Report
BMI View: We significantly downgraded our short-term outlook for the Saudi
Arabian construction sector on the back of liquidity in the market severely
drying up, following a reduction in government spending. Beyond 2016 the goals
of Vision 2030 will be key to opening up the infrastructure market with the
potential of private investment
Saudi Arabia Pharmaceuticals and Healthcare Report
BMI View: The combined value of Saudi Arabia's pharmaceutical and healthcare
markets is the largest in the Middle East and Africa region. The Kingdom's
National Transformation Program, a key part of Vision 2030, reinstates the
government's commitment to improving healthcare provision in the country.
Nonetheless, the rising burden of non
Saudi Arabia Petrochemicals Report
The Saudi government is targeting national petrochemicals output of 115mn
tonnes in 2016, which represents a 46% increase since 2013. There are 26
petrochemicals projects under construction at a cost of USD15bn while another 42
are planned over the next five years at an estimated cost of USD46bn. However,
there is the ongoing threat fro